Person:
TUĞLULAR, ZÜBEYDE SERHAN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

TUĞLULAR

First Name

ZÜBEYDE SERHAN

Name

Filters

2007 - 200912010 - 20142
Reset filters

Settings

Author: KOÇ, MEHMET × Subject: CARDIOVASCULAR RISK ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Fibroblast Growth Factor-23 Levels Are Associated With Uric Acid But Not Carotid Intima Media Thickness in Renal Transplant Recipients
    (ELSEVIER SCIENCE INC, 2014) VELİOĞLU, ARZU; Asicioglu, E.; Kahveci, A.; Arikan, H.; Koc, M.; Tuglular, S.; Ozener, C.
    Introduction. Cardiovascular disease (CVD) is the leading cause of mortality in chronic kidney disease (CKD) patients. Fibroblast growth factor-23 (FGF-23) is associated with atherosclerosis and cardiovascular mortality in CKD patients and healthy subjects. However, data in renal transplant recipients (RTR) are scarce. We aimed to determine factors associated with FGF-23 and to explore its relationship to atherosclerosis. Methods. Forty-six patients and 44 controls were included. FGF-23 was measured from plasma. Carotid intima media thickness (CIMT) was evaluated ultrasonographically. Results. Patients had higher waist circumference (WC; 92.2 +/- 14.9 vs 85.3 +/- 11.0 cm; P < .05), glucose (99.8 +/- 17.2 vs 90.3 +/- 6.5 mg/dL; P < .01), creatinine (1.43 +/- 0.6 vs 0.86 +/- 0.1 mg/dL; P < .01), triglyceride (160.4 +/- 58.9 vs 135.6 +/- 59.8 mg/dL; P < .05), white blood cells (WBC; 7938.6 +/- 2105.2 vs 6715.7 +/- 1807.5 WBC/mm(3); P < .01), ferritin (217.0 +/- 255.8 vs 108.3 +/- 142.4 ng/mL; P < .05), uric acid (6.5 +/- 1.6 vs 4.7 +/- 1.3 mg/dL; P < .01), C-reactive protein (CRP; 8.2 +/- 18.2 vs 5.3 +/- 7.9 mg/L; P < .01), parathyroid hormone (PTH; 89.7 +/- 59.2 vs 44.1 +/- 16.7 pg/mL; P < .01), and alkaline phosphatase (ALP; 162.5 +/- 86.6 vs 74.2 +/- 21.9 U/L; P < .01). FGF-23 was higher in patients (11.7 +/- 7.2 vs 9.6 +/- 6.8 pg/mL; P < .05). CIMT was similar (0.58 +/- 0.09 vs 0.57 +/- 0.1 mm; P > .05). WC, creatinine, and uric acid were positively correlated with FGF-23, whereas albumin showed negative correlation. On multivariate analysis only creatinine and uric acid were determinants of FGF-23. Conclusion. FGF-23 levels are associated with uric acid in RTR. Larger studies are needed to confirm this finding.
  • Thumbnail Image
    PublicationOpen Access
    Fibroblast Growth Factor-23 Levels Are Associated with Vascular Calcifications in Peritoneal Dialysis Patients
    (KARGER, 2013) VELİOĞLU, ARZU; Asicioglu, Ebru; Kahveci, Arzu; Arikan, Hakki; Koc, Mehmet; Tuglular, Serhan; Ozener, Cetin Ishak
    Background: The aim of the study was to assess the relationship between fibroblast growth factor-23 (FGF-23) and vascular calcifications (VC) in peritoneal dialysis (PD) patients. Methods: A cross-sectional study was performed in 55 PD patients who underwent pelvic X-ray to assess for VC. Patients with and without linear calcifications were recorded. Results: Fifteen patients (27.3%) had linear calcifications on pelvic X-ray. FGF-23 levels were higher in patients with VC (299.5 (30.4-2,410.0) vs. 74.4 (14.8-1,030) pg/ml, p < 0.01). Diabetic patients had lower FGF-23 values (43.2 (14.9-134.0) vs. 103.5 (14.8-2,410) pg/ml, p < 0.01). Patients with residual renal function (RRF) had lower FGF-23 levels (70.6 (14.8-513) vs. 179.5 (30.4-2,410) pg/ml, p = 0.06); however, this did not reach statistical significance. FGF-23 levels, age, creatinine, Ca, dialysis duration and HbA1c were positively correlated with VC, whereas RRF, Ca intake and ALP were negatively associated. Multivariate logistic analysis confirmed FGF-23 levels, age, dialysis duration and RRF to be associated with VC. Conclusions: FGF-23 levels are associated with VC in PD patients. Further studies are needed to clarify whether it is simply a marker or a potential factor. It may prove to be an important therapeutic target for VC management. (C) 2013 S. Karger AG, Basel
  • No Thumbnail Available
    PublicationMetadata only
    Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients
    (TAYLOR & FRANCIS LTD, 2007) ARIKAN, İZZET HAKKI; Arikan, Hakki; Koc, Mehmet; Sari, Hakan; Tuglular, Serhan; Ozener, Cetin; Akoglu, Emel
    Background. Apolipoprotein-E (ApoE) gene polymorphism has an important role in lipoprotein metabolism and could participate in the development of cardiovascular diseases (CVD). Plasminogen activator inhibitor-1 (PAI-1) is also regarded as a risk factor for CVD. The aim of the present study is to further investigate the possible link(s) between ApoE gene polymorphism and plasma PAI-1 antigen and serum lipid profile in peritoneal dialysis (PD) and hemodialysis (HD) patients. Material and Methods. We studied 72 PD patients (38 female, mean age 49.9 +/- 16.1 years), 72 HD patients (22 female, mean age 57.4 +/- 14.6 years), and 42 healthy subjects (21 female, mean age 50.1 +/- 18.6 years). Serum lipid parameters, plasma PAI-1 levels, and ApoE genotypes were determined in all subjects. Results. The distribution of ApoE genotypes and alleles frequencies was similar in dialysis patients and healthy controls. In PD patients, total cholesterol (TC), low-density lipoprotein (LDL)-C, and ApoB levels were significantly higher than that of HD patients. HD patients with E3/4 genotype had elevated TC, LDL-C and ApoB levels compared with E3/3 genotype. TC and triglyceride levels were also higher in E3/4 genotype than that of E2/3 genotype. PD and HD patients showed a significantly increased PAI-1 level s compared with controls, whereas PAI-1 levels were highest in HD patients. There was no significant relation between ApoE genotypes and PAI-1 levels. Conclusions. The present study suggests that ApoE polymorphism significantly affects serum lipid profile in HD patients and epsilon 4 allele carriers are more susceptible to have atherogenic lipid profile.